772 results about "Hepatic Diseases" patented technology

A system has been constructed that recapitulate the features of a capillary bed through normal human tissue. The system facilitates perfusion of three-dimensional (3D) cell monocultures and heterotypic cell co-cultures at the length scale of the capillary bed. A major feature is that the system can be utilized within a “multiwell plate” format amenable to high-throughput assays compatible with the type of robotics commonly used in pharmaceutical development. The system provides a means to conduct assays for toxicology and metabolism and as a model for human diseases such as hepatic diseases, including hepatitis, exposure-related pathologies, and cancer. Cancer applications include primary liver cancer as well as metastases. The system can also be used as a means of testing gene therapy approaches for treating disease and inborn genetic defects.

The present invention concerns compounds, compositions, and methods for the study, diagnosis, and treatment of diseases and conditions associated with alpha-1 antitrypsin (AAT) allelic variants that respond to the modulation of gene expression and / or activity. The present invention also concerns compounds, compositions, and methods relating to diseases and conditions associated with alpha-1 antitrypsin (AAT) allelic variants that respond to the modulation of expression and / or activity of genes involved in alpha-1 antitrypsin (AAT) gene expression pathways or other cellular processes that mediate the maintenance or development of alpha-1 antitrypsin (AAT) diseases and conditions such as liver disease, lung disease, and any other diseases or conditions that are related to or will respond to the levels of an alpha-1 antitrypsin (AAT) variant protein in a cell or tissue, alone or in combination with other therapies. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against the expression disease related genes or alleles having alpha-1 antitrypsin (AAT) sequences.

The present invention provides a novel method of synthesizing branched galactose-terminal glycoproteins. A number of these glycoproteins have binding affinity to the asialoglycoprotein receptor. The present invention also provides novel conjugates having branched galactose-terminal glycoproteins that is complexed to a therapeutically effective agent, such as an isolated protein, polysacharides, lipids and radioactive isotope. These conjugates may be used to deliver the therapeutically effective agent to mammalian cells generally, and to hepatocytes specifically.

A system has been constructed that recapitulate the features of a capillary bed through normal human tissue. The system facilitates perfusion of three-dimensional (3D) cell monocultures and heterotypic cell co-cultures at the length scale of the capillary bed. A major feature is that the system can be utilized within a “multiwell plate” format amenable to high-throughput assays compatible with the type of robotics commonly used in pharmaceutical development. The system provides a means to conduct assays for toxicology and metabolism and as a model for human diseases such as hepatic diseases, including hepatitis, exposure-related pathologies, and cancer. Cancer applications include primary liver cancer as well as metastases. The system can also be used as a means of testing gene therapy approaches for treating disease and inborn genetic defects.

Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.

A system for selectively delivering drugs to target tissues is provided. The system includes a drug-linker-saccharide-drug conjugate (D-L-A-D1). The linker includes a functional group that is recognized and cleaved by enzyme in the target phases. The recognition segment is preferably a malaria drugs. The carrier is preferably hydrophilic, biodegradable and biocompatible particle. Any drug may be delivered using a conjugate prepared according to the invention.

The present invention provides a herbal pharmaceutical composition for treating patients with liver diseases and / or HIV. The composition contains fifteen (15) ingredients, which are diffuse hedyotis, bistort rhizome, giant knotweed rhizome, Asiatic moonseed rhizome, baical skullcap root, bovine biliary powder, milkvetch root, barbary wolfberry fruit, sanqi, red ginseng, figwort root, Chinese magnoliavine fruit, turmeric root-tuber, hawthorn fruit, and Chinese angelica. Among the fifteen (15) ingredients, diffuse hedyotis, bistort rhizome, giant knotweed rhizome, and Chinese magnoliavine fruit are the required herbs which contribute to the efficacy of the pharmaceutical composition.

A method of treating liver disease in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality.

A method of treating liver disease in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.

The present invention is directed to a method for treating a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, comprising the step of increasing the ratio of dopaminergic neuronal to noradrenergic neuronal activity within the central nervous system and particularly the hypothalamus of the central nervous system of the patient.In another aspect, the present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject. The present invention is also directed to pharmaceutical compositions that include the above compounds and a pharmaceutically acceptable carrier.

A method of treating liver disease in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and / or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.

Provided are methods for selectively expressing therapeutic molecules, such as secretory proteins, antisense molecules and ribozymes, in the liver. The methods find use in treating hepatic diseases or conditions. The methods also find use in treating any disease or condition in which systemic administration of the therapeutic substance, for example, a secretory protein, is desired. The methods involve administering to a mammalian patient having a need for liver expression of a therapeutic molecule an AAV vector containing a therapeutically effective amount of the therapeutic molecule. Also provided are novel vectors employable in these methods.

Antagonistic synthetic peptides, obtained from TGFβ1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment of liver diseases and more concretely in cases of fibrosis. The said compositions can optionally include mimotopes of the said active peptides.

The invention discloses fruit vinegar tea drink. The fruit vinegar tea drink is prepared from the following raw materials in part by weight: 50 to 70 parts of apple juice, 5 to 8 parts of white granulated sugar, 1 to 2 parts of honey and 1 to 1.2 parts of black tea powder. A preparation method comprises the following steps of: adding concentrated apple juice into fruit vinegar tea serving as a main raw material, wherein the fruit vinegar tea is prepared from fresh apple juice, black tea powder, white granulated sugar and honey, which serve as main raw materials, through biological engineering submerged secondary fermentation; and mixing, performing superhigh temperature instant sterilization, and performing encapsulation at medium temperature to obtain health-care drink with various nutrients. The fruit vinegar tea drink has high content of nutritional ingredients, good mouthfeel and can meet requirements of people on health-care drink. The fruit vinegar tea has effects of eliminating fatigue, reducing morbidity of liver diseases, resisting ageing, softening blood vessels, reducing blood fat, reducing cholesterol and preventing and treating obesity, and has high sterilization ability; apple vinegar and black tea are integrated into a whole; requirements of people on health promotion are met due to the combination of the apple vinegar and the black tea; and the apple vinegar and the black tea can be mutually promoted and supplemented.

The invention discloses a pyridines compound for treating liver diseases. The compound is a compound as shown in a formula I, pharmacologically acceptable salt, a hydrate, a solvate or a metabolite ofthe compound. The compound can be used for preparing a medicine for treating and / or preventing the liver diseases.

Antagonistic synthetic peptides, obtained from TGFβ1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment of liver diseases and more concretely in cases of fibrosis. The said compositions can optionally include mimotopes of the said active peptides.

An organ fibrosis inhibitor, in particular, a liver fibrosis inhibitor is provided, which contains histidine, preferable together with cysteine and / or cystine as active ingredients. Owing to the combined use, a remarkable effect of inhibiting organ fibrosis, in particular, liver fibrosis can be shown. These substances are usable as the desired active ingredients in the form of a drug or in the form of a food and drink. There is also provided an organ fibrosis inhibitor comprising the active ingredients as described above either separately or as a combination of one of them with a mixture of the other two ingredients. Thus, it is possible to present organ fibrosis inhibitors such as a liver fibrosis inhibitor which are applicable in the form used in health foods for improving and maintaining liver function and foods and drinks for sick people, as well as drugs for various organ diseases caused by fibrosis such as liver diseases.

The invention discloses an oleanolic acid couple, which is a nitric oxide donator type OLA derivative coupled by dissimilar NO donators with hepatic disease treating medicament oleanolic acid (OLA) through binding groups with ester bonds or amido bonds, wherein the suppressor cell apoptosis action of some of the compounds is stronger than that of the NCX-10000 that are undergone US stage I clinical research, thus may possibly be used for the treatment of hepatitis and cirrhosis.

The present invention provides a fully nutritional formula product with special medical purposes for liver diseases. The fully nutritional formula product is characterized by comprising the following materials in proportions: pre-digested carbohydrates, compound proteins, compound fats, medicinally and edibly homologous biological resources, dietary fibers, mineral premixes, vitamin premixes, moringa oleifera powder, cyclic adenosine monophosphate, etc. The product combines the metabolic characteristics and the nutritional requirements of patients with the liver diseases, and specially the medicinally and edibly homologous biological resource ingredients beneficial to the patients with the liver diseases are added. The product can improve the malnutrition status of the patients with the liver diseases, protects liver cells and promotes the repair and regeneration of the liver cells. Besides, the product is good in palatability, convenient for combination and uses, and easy for the patients with the liver disease to accept.

The present invention provides novel 1,3,5-triazinane-2,4,6-trione derivatives, such as compounds of any one of Formulae (I) and (II), and salts thereof, and methods of preparing the compounds. Also provided are compositions including a compound of the invention and an agent (e.g., an siRNA, mRNA, or plasmid DNA). The present invention also provides methods and kits using the compositions for delivering an agent to a subject (e.g., to the liver, spleen, or lung of the subject) or cell and for treating and / or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, liver diseases, and lung diseases.

The invention discloses a method for automatically segmenting liver tumors in abdominal CT sequence images. The method comprises the following steps of: preprocessing: preprocessing an abdominal CT sequence image so as to obtain a liver area in the image; liver enhancement: improving a contrast ratio of normal liver parenchyma to tumor tissue by adoption of a segmented nonlinear enhancement operation and an iterative convolution operation according to a grey level distribution characteristic of the liver area; automatic segmentation: constructing an image segmentation energy function for multi-target segmentation by utilizing the enhancement result and combining image boundary information, minimizing the energy function by adoption of an optimal algorithm and obtaining a liver tumor preliminary automatic segmentation result; and post-processing: optimizing the preliminary segmentation result by adoption of a three-dimensional mathematic morphological open operation, and removing mis-segmented areas to improve the segmentation precision. The method is beneficial for helping radiological experts and surgeons to timely and effectively obtaining overall information and three-dimensional display of liver tumors and providing technical support for computer-aided diagnosis and treatment of liver diseases.

The invention relates to a Tibetan medicinal preparation for treating liver diseases. The Tibetan medicinal preparation for treating the liver diseases consists of the following ingredients in part by weight: 78 to 127 parts of calcite (calcined), 6 to 10 parts of sandalwood, 12 to 20 parts of rosewood heart wood, 8 to 12 parts of Chinese eaglewood, 15 to 25 parts of myrobalan (denucleated), 3 to5 parts of cardamine, 8 to 12 parts of safflower, 6 to 10 parts of concretio silicea bambusae, 3 to 5 parts of nutmeg, 3 to 5 parts of tsaoko amomum fruit, 12 to 20 parts of emblic leafflower fruit, 9 to 15 parts of seed of pomegranate, 5 to 8 parts of semen holarrhenae, 6 to 10 parts of long pepper extract, 6 to 10 parts of costustoot, 12 to 20 parts of herba dracocephali tangutici, 1.2 to 2 parts of swertia pseudochinensis hara, 8 to 12 parts of Baxiaga, 12 to 20 parts of meconopsis, 6 to 10 parts of herpetospermum pedunculosum, 12 to 20 parts of herba aconiti tangutici, 1.6 to 2.5 parts ofin-vitro cultivation bezoar and 0.8 to 1.3 parts of artificial musk. The Tibetan medicinal preparation for treating the liver diseases has obvious curative effects on various diseases. All-natural Tibetan medicinal plants serve as raw materials and no auxiliary materials are added, so the Tibetan medicinal preparation does not have any side effect on a human body, can effectively improve the bioavailability of the human body and can improve human immunity.

The invention relates to a special clinical nutrient composition for liver diseases and a preparation method of the composition. The special clinical nutrient composition comprises protein, fat, carbohydrate, dietary fibers, macro-elements, trace elements, vitamins, dietary essence, medicinal and edible components, natural plant compounds and new resource food, wherein the new resource food comprises hyriopsis cumingii polysacchride, and the medicinal and edible components comprise mint, Indian bread, barbary wolfberry fruits, common floweringquince fruits, common yam rhizome, mulberry fruits, spina date seeds and citrons. The preparation method includes the steps: preparing the components into powder in advance; uniformly mixing the powder to prepare corresponding dosage forms. The medicinal and edible components are subjected to water extraction, concentration and spray drying to prepare the powder, and the vitamins and the fat are microencapsulated into the powder. By screening and matching the components, the nutrient composition can provide needed energy, key nutrients and necessary trace elements for patients suffering from the liver diseases, the liver diseases are treated and liver cells are protected under the synergistic action of the components, and development of the liver diseases is slowed down.

The invention relates to the field of biological medicine, and in particular relates to liver targeted medicine. The medicine is chemical micromolecular medicine connecting galactosamine. The chemicalmicromolecular medicine is medicine for treating liver diseases or liver-related diseases. The chemical micromolecular medicine is prepared from but not limited to thyroxine T3, sorafenib, taxol, regorafenib, lamivudine, entecavir, telbivudine, statins, fibrates, niacin, bile acid sequestrants, other hepatitis virus DNA (RNA) polymerase inhibition compounds and the like. The galactosamine is tervalent acetylgalactosamine. The connection is the direct connection of the galactosamine and the chemical micromolecular medicine or the connection through linking fragments; the linking fragments comprise but not limited to carbon chains, disulfide bonds, pyrophosphate diester, cysteic acid, polypeptide and thioether or valine-citrulline. The medicine provided by the invention has the advantages that the liver targeted performance is improved; the medicine curative effect is enhanced; the toxic and side reactions on other non-targeted tissues are few.

The present invention provides a pharmaceutical composition for the prevention and treatment of a non-alcoholic fatty liver disease (NAFLD), containing an active ingredient selected from the group consisting of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof. Further, the present invention provides a method for the prevention or treatment of a non-alcoholic fatty liver disease, including administering an effective amount of an active ingredient selected from the group consisting of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof to a mammal including a human in need thereof.; Further, the present invention provides use of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof, for manufacturing a pharmaceutical composition for the prevention or treatment of a non-alcoholic fatty liver disease.

The invention provides a new compound which has certain agonist activity on a Farnesoid X receptor (FXR) and is used for treating FXR mediated diseases and / or symptoms such as liver disease and gastrointestinal disease. (The formula is shown in the description.).

Provided is a compound represented by the formula (1):wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and / or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.

An organ fibrosis inhibitor, in particular, a liver fibrosis inhibitor is provided, which contains histidine, preferable together with cysteine and / or cystine as active ingredients. Owing to the combined use, a remarkable effect of inhibiting organ fibrosis, in particular, liver fibrosis can be shown. These substances are usable as the desired active ingredients in the form of a drug or in the form of a food and drink. There is also provided an organ fibrosis inhibitor comprising the active ingredients as described above either separately or as a combination of one of them with a mixture of the other two ingredients. Thus, it is possible to present organ fibrosis inhibitors such as a liver fibrosis inhibitor which are applicable in the form used in health foods for improving and maintaining liver function and foods and drinks for sick people, as well as drugs for various organ diseases caused by fibrosis such as liver diseases.